-+ 0.00%
-+ 0.00%
-+ 0.00%

Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?

The Motley Fool·09/28/2026 15:02:22
Listen to the news

Moderna (NASDAQ: MRNA) has delivered the pivotal cancer result investors were waiting for, while BioNTech Se (NASDAQ: BNTX) offers greater financial flexibility and a broader oncology pipeline. The question is whether Moderna's stronger clinical proof deserves its valuation premium, or whether BioNTech's multiple paths to success create the more attractive long-term setup.

Stock prices used were the market prices of Sept. 11, 2026. The video was published on Sept. 28, 2026.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se and Moderna. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.